ACRS News and Press, Aclaris Therapeutics Inc. From 05/17/21

WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a...

Millions of people all over the world deal with arthritic pain. In fact, just in the U.S., the Centers for Disease Control and Prevention (CDC), says about 23% of adults are dealing with it. Nearly 24 million are limited with their activities because of it, with about 25% of people reportin...

Aclaris Therapeutics (ACRS): Q1 GAAP EPS of -$0.57 misses by $0.29.Revenue of $1.78M (+26.2% Y/Y) beats by $0.3M.Press Release For further details see: Aclaris Therapeutics EPS misses by $0.29, beats on revenue

Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021 Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe Rheumatoid Arthritis in Second Half of 2021 Advancing ATI-450 int...

The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this event. For further details see: Aclaris Therapeutics (ACRS) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow

Aclaris Therapeutics ([[ACRS]] -4.7%) has completed the enrollment of a Phase 2a trial of ATI-1777, an investigational topical “soft” Janus kinase ("JAK") 1/3 inhibitor, in the treatment of moderate to severe atopic dermatitis (“AD”).The multicenter, rand...

Enrollment Completed Data Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, tod...

BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating. ATI-450 is a novel oral MK2 inhibitor that demonstrated comparable efficacy and superior safety over Jak inhibitors during Ph2. The oral route of administration offers a superior convenience over biological...

Aclaris Therapeutics (ACRS): Q4 GAAP EPS of -$0.30 misses by $0.04.Revenue of $1.58M (+43.6% Y/Y) beats by $0.19M.Shares -3.2% PM.Press Release For further details see: Aclaris Therapeutics EPS misses by $0.04, beats on revenue

Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid...